Skip Navigation LinksHome > September 2014 - Volume 27 - Issue 9 > Canagliflozin: A new option for managing diabetes
Journal of the American Academy of Physician Assistants:
doi: 10.1097/01.JAA.0000453247.76333.09
What's New in Diabetes

Canagliflozin: A new option for managing diabetes

Livingston, Molly PharmD; Clements, Jennifer N. PharmD, BCPS, CDE, BCACP

Collapse Box


ABSTRACT: Canagliflozin is a sodium glucose cotransporter 2 inhibitor for patients with type 2 diabetes and can be given as monotherapy or in combination with other agents, including insulin. Taken orally once daily, canagliflozin can reduce weight and BP, but has been associated with genital mycotic infections.

© 2014 American Academy of Physician Assistants.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.